Growing Risk of Cardiovascular Disease Amid Surge in Obesity, Diabetes and Hypertension Cases Drives the Global Cholesterol Testing Market

The global market for Cholesterol Screening and Lab Testing Services is projected to reach US$17.4 billion by 2024, driven by rising prevalence of Cardiovascular Diseases amid growing incidence of obesity, diabetes, and hypertension, and ageing population.

Cholesterol is a naturally occurring white crystalline lipid that is generally present in human body. Synthesized by the liver, cholesterol plays a crucial role as a vital constituent of cell membranes and is required for the production of steroid hormone and bile acids. Although, cholesterol is vital for proper functioning of the body, excess levels of cholesterol, found mainly as low-density lipoprotein (LDL), pose a health risk. Also known as 'bad' cholesterol, LDL is a known risk factor for cardiovascular diseases (CVDs) such as coronary heart disease, rheumatic heart disease, stroke and high blood pressure (hypertension). Given the fatal impact of CVDs, cholesterol screening tests are a compulsion for people deemed to be at risk of these diseases. Different types of tests are carried out to quantify the level of cholesterol such as Complete Lipid Profile / Lipid Panel Test, Apolipoprotein B, and Apolipoprotein A1 among others.

Demand for cholesterol screening and lab testing services continues to increase across the world, primarily stimulated by growing awareness over the importance of cholesterol screening as a measure to reduce fatality and improve diagnosis and treatment of CVD. Pressing need for regular cholesterol testing among people with family history of heart disease, individuals with diabetes and obesity, and aged people, who are regarded to be at the risk of cardiovascular disease, is aiding the demand for cholesterol testing. Further, cholesterol testing market is also benefiting from prevailing macro trends in the global healthcare sector such as increasing healthcare expenditure, wider availability of care/diagnostics services, growing health-consciousness and lenience towards preventive care among urban population. While the number of patients seeking cholesterol screening based on doctor's recommendation continues to grow substantially, volumes of consumer-initiated tests also saw incremental growth in recent years. Uptrend in cholesterol testing is immensely benefiting the commercial diagnostics centers, hospitals with in-house laboratories, and other entities offering diagnostics services. On the other hand, growing popularity of self-testing home kits, which can be operated by patient himself to precisely generate cholesterol levels, is niggling the market prospects of full-service diagnostics services providers.



The United States ranks as the largest market, worldwide. On the other hand, Asia-Pacific represents the fastest growing regional market, trailing at a CAGR of 13.3% over the analysis period. Rising disposable incomes, coupled with increasing urbanization, growing health consciousness, aging population, and awareness of the need for cardiovascular risk assessments are fuelling demand for cholesterol screening services in the Asia-Pacific region. The market is also benefiting from focused investments on improving healthcare infrastructure and growing base of at-risk population in China and India.
Major players in the market include Abbott Laboratories, AccuTech LLC, Akers Biosciences Inc., Alere Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., Boston Heart Diagnostics Corporation, Eurofins Scientific, Home Access Health Corporation, Laboratory Corporation of America Holdings, PRIMA Lab SA, PTS Diagnostics, Quest Diagnostics Inc., Randox Laboratories Ltd., Roche Diagnostics, Sekisui Diagnostics LLC, Siemens Healthineers, and Sigma-Aldrich Corp. among others.

View infographic | Report TOC